Advanced search
Publication Cover
Experimental Lung Research Volume 44, 2018 - Issue 6
Submit an article Journal homepage
96
Views
8
CrossRef citations to date
0
Altmetric
Original Article

The effect of microRNA-129 on the migration and invasion in NSCLC cells and its mechanism

Cao BinDepartment of Thoracic-Cardio Surgery, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, ChinaCorrespondence[email protected]
,
He XiaofengDepartment of Thoracic-Cardio Surgery, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
&
Xu WanziDepartment of Thoracic-Cardio Surgery, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
Pages 280-287 | Received 30 May 2018, Accepted 10 Oct 2018, Published online: 26 Nov 2018

References

  • Blair HA. Atezolizumab: a review in previously treated advanced non-small cell lung cancer. Target Oncol. 2018. doi:10.1007/s11523-018-0570-5.
  • Deslypere G, Gullentops D, Wauters E, et al. Immunotherapy in non-metastatic non-small cell lung cancer: can the benefits of stage IV therapy be translated into earlier stages? Ther Adv Med Oncol. 2018;10:1758835918772810. doi:10.1177/1758835918772810.
  • Reck M, Garassino MC, Imbimbo M, et al. Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting. Lung Cancer. 2018;120:62–69. doi:10.1016/j.lungcan.2018.03.025.
  • Lu J, Zhan Y, Feng J, et al. MicroRNAs associated with therapy of non-small cell lung cancer. Int J Biol Sci. 2018;14(4):390–397. doi:10.7150/ijbs.22243.
  • Moretti F, D'Antona P, Finardi E, et al. Systematic review and critique of circulating miRNAs as biomarkers of stage I-II non-small cell lung cancer. Oncotarget. 2017;8(55):94980–94996. doi:10.18632/oncotarget.21739.
  • Xiao Y, Li X, Wang H, et al. Epigenetic regulation of miR-129-2 and its effects on the proliferation and invasion in lung cancer cells. J Cell Mol Med. 2015;19(9):2172–2180. doi:10.1111/jcmm.12597.
  • Liu MX, Zhou KC, Cao Y. MCRS1 overexpression, which is specifically inhibited by miR-129*, promotes the epithelial-mesenchymal transition and metastasis in non-small cell lung cancer. Mol Cancer. 2014;13(1):245. doi:10.1186/1476-4598-13-245.
  • Chen X, Zhang L, Zhang T, et al. Methylation-mediated repression of microRNA 129-2 enhances oncogenic SOX4 expression in HCC. Liver Int. 2013;33(3):476–486. doi:10.1111/liv.12097.
  • Xiao L, Zhou X, Liu F, et al. MicroRNA-129-5p modulates epithelial-to-mesenchymal transition by targeting SIP1 and SOX4 during peritoneal dialysis. Lab Invest. 2015;95(7):817–832. doi:10.1038/labinvest.2015.57.
  • Chen X, Ruan A, Wang X, et al. miR-129-3p, as a diagnostic and prognostic biomarker for renal cell carcinoma, attenuates cell migration and invasion via downregulating multiple metastasis-related genes. J Cancer Res Clin Oncol. 2014;140(8):1295–1304. doi:10.1007/s00432-014-1690-7.
  • Asgarova A, Asgarov K, Godet Y, et al. PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in non-small cell lung carcinoma. Oncoimmunology. 2018; 7(5):e1423170. doi:10.1080/2162402x.2017.1423170.
  • Tian J, Luo Y, Xiang J, et al. Combined treatment for non-small cell lung cancer and breast cancer patients with brain metastases with whole brain radiotherapy and temozolomide: a systematic review and meta-analysis. J Neurooncol. 2017;135(2):217–227. doi:10.1007/s11060-017-2572-z.
  • Lu C, Shan Z, Li C, et al. MiR-129 regulates cisplatin-resistance in human gastric cancer cells by targeting P-gp. Biomed Pharmacother. 2017;86:450–456. doi:10.1016/j.biopha.2016.11.139.
  • Ma N, Chen F, Shen SL, et al. MicroRNA-129-5p inhibits hepatocellular carcinoma cell metastasis and invasion via targeting ETS1. Biochem Biophys Res Commun. 2015;461(4):618–623. doi:10.1016/j.bbrc.2015.04.075.
  • Jiang Z, Wang H, Li Y, et al. MiR-129-5p is down-regulated and involved in migration and invasion of gastric cancer cells by targeting interleukin-8. Neo. 2016;63(5):673–680. doi:10.4149/neo_2016_503.
  • Luan QX, Zhang BG, Li XJ, et al. MiR-129-5p is downregulated in breast cancer cells partly due to promoter H3K27m3 modification and regulates epithelial-mesenchymal transition and multi-drug resistance. Eur Rev Med Pharmacol Sci. 2016;20(20):4257–4265.
  • Li S, Qin X, Li Y, et al. MiR-133a suppresses the migration and invasion of esophageal cancer cells by targeting the EMT regulator SOX4. Am J Transl Res. 2015;7(8):1390–1403.
  • Wang B, Li Y, Tan F, et al. Increased expression of SOX4 is associated with colorectal cancer progression. Tumor Biol. 2016;37(7):9131–9137. doi:10.1007/s13277-015-4756-5.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.